Provided by Tiger Trade Technology Pte. Ltd.

Esperion Therapeutics

3.69
+0.520016.40%
Post-market: 3.710.0200+0.54%17:42 EST
Volume:19.16M
Turnover:69.47M
Market Cap:882.14M
PE:-6.89
High:3.77
Open:3.28
Low:3.28
Close:3.17
52wk High:3.94
52wk Low:0.6925
Shares:239.06M
Float Shares:237.00M
Volume Ratio:2.93
T/O Rate:8.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5358
EPS(LYR):-0.2764
ROE:97.76%
ROA:-5.42%
PB:-1.95
PE(LYR):-13.35

Loading ...

Esperion Therapeutics Q2 2025: Revenue Up 12% Y/Y to $82.4M, U.S. Net Product Revenue Jumps 42%, Net Loss Narrows to $4.8M, EPS at $0.02

Reuters
·
Aug 05

Esperion Therapeutics - NOW Expects to Achieve Sustainable Profitability Beginning Q1 2026

THOMSON REUTERS
·
Aug 05

Esperion Therapeutics - Reiterates Expectation for FY Operating Expenses Between $215 Mln-$235 Mln

THOMSON REUTERS
·
Aug 05

Esperion Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
Aug 01

BB Biotech AG Reports Q2 2025 Net Loss of CHF 100 Million; USD Share Price Up 10.2%, Currency Drag Impacts CHF Performance

Reuters
·
Jul 25

Esperion Therapeutics Inc. to Announce Second Quarter 2025 Financial Results

Reuters
·
Jul 22

Esperion Therapeutics CFO Benjamin Halladay Reports Disposal of Common Shares

Reuters
·
Jul 19

Esperion Therapeutics Inc. Reaches Settlement to Delay Generic NEXLETOL Launch Until 2040

Reuters
·
Jul 08

Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

GlobeNewswire
·
Jul 08

Esperion Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director John Craig Thompson

Reuters
·
Jul 02

Esperion Therapeutics Appoints Craig Thompson to Board of Directors, Bringing Extensive Biopharmaceutical Expertise

Reuters
·
Jul 01

CFO Benjamin Halladay Reports Disposal of Common Shares in Esperion Therapeutics Inc

Reuters
·
Jun 19

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 17

Esperion Therapeutics Inc. Concluded Annual Stockholders Meeting

Reuters
·
Jun 03

Esperion Therapeutics Settles Patent Litigation, Delays Generic NEXLETOL Until 2040

Reuters
·
Jun 02